VIP Gene Deletion in Mice Causes Cardiomyopathy Associated with Upregulation of Heart Failure Genes

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Szema, Anthony M ^a,b   Hamidi, Sayyed A ^a,b   Smith, S David ^c   Benveniste, Helene ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c BROOKHAVEN NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIAC IMAGING; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE; GENE DELETION; GENE OVEREXPRESSION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE METABOLISM; HEART RIGHT VENTRICLE HYPERTROPHY; MALE; MICROARRAY ANALYSIS; MOUSE; MYH1 GENE; MYLPF GENE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PULMONARY HYPERTENSION; SYSTOLIC DYSFUNCTION; TNNC2 GENE; TNNT3 GENE; VASOACTIVE INTESTINAL POLYPEPTIDE GENE; WILD TYPE;

ANIMALS; CARDIOMYOPATHIES; FEMALE; GENE DELETION; HEART FAILURE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; STROKE VOLUME; TRANSCRIPTOME; UP-REGULATION; VASOACTIVE INTESTINAL PEPTIDE;

EID: 84877879173     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061449     Document Type: Article

References (32)

1. McCann C, Gopalan D, Sheares K, Screaton N, (2012) Imaging in pulmonary hypertension, part 1: clinical perspectives, classification, imaging techniques and imaging algorithm. Postgrad Med J 88: 271-279.
2. McLaughlin VV, Genthner DE, Panella MM, Rich S, (1998) Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 338: 273-277.
3. Raiesdana A, Loscalzo J, (2006) Pulmonary arterial hypertension. Ann Med 38: 95-110.
4. Alan B, Nalbantgil S, (2010) [Genetic, cellular and molecular mechanisms of pulmonary arterial hypertension]. Anadolu Kardiyol Derg 10Suppl 1: 9-13.
5. Swetz KM, Shanafelt TD, Drozdowicz LB, Sloan JA, Novotny PJ, et al. (2012) Symptom burden, quality of life, and attitudes toward palliative care in patients with pulmonary arterial hypertension: Results from a cross-sectional patient survey. J Heart Lung Transplant 31: 1102-1108.
6. Said SI, Hamidi SA, Dickman KG, Szema AM, Lyubsky S, et al. (2007) Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene. Circulation 115: 1260-1268.
7. Szema AM, Hamidi SA, Lyubsky S, Dickman KG, Mathew S, et al. (2006) Mice lacking the VIP gene show airway hyperresponsiveness and airway inflammation, partially reversible by VIP. Am J Physiol Lung Cell Mol Physiol 291: L880-886.
8. Shedeed SA, (2010) Right ventricular function in children with bronchial asthma: a tissue Doppler echocardiographic study. Pediatr Cardiol 31: 1008-1015.
9. St Hilaire RC, Murthy SN, Kadowitz PJ, Jeter JR Jr, (2010) Role of VPAC1 and VPAC2 in VIP mediated inhibition of rat pulmonary artery and aortic smooth muscle cell proliferation. Peptides 31: 1517-1522.
10. Hamidi SA, Prabhakar S, Said SI, (2008) Enhancement of pulmonary vascular remodelling and inflammatory genes with VIP gene deletion. Eur Respir J 31: 135-139.
11. Kim J, Ruff M, Karwatowska-Prokopczuk E, Hunt L, Ji H, et al. (1998) HIV envelope protein gp120 induces neuropeptide Y receptor-mediated proliferation of vascular smooth muscle cells: relevance to AIDS cardiovascular pathogenesis. Regul Pept 75-76: 201-205.
12. Maruno K, Absood A, Said SI, (1995) VIP inhibits basal and histamine-stimulated proliferation of human airway smooth muscle cells. Am J Physiol 268: L1047-1051.
13. Miyata A, Sato K, Hino J, Tamakawa H, Matsuo H, et al. (1998) Rat aortic smooth-muscle cell proliferation is bidirectionally regulated in a cell cycle-dependent manner via PACAP/VIP type 2 receptor. Ann N Y Acad Sci 865: 73-81.
14. Oiso Y, Kotoyori J, Murase T, Ito Y, Kozawa O, (1993) Effect of pituitary adenylate cyclase activating polypeptide on vasopressin-induced proliferation of aortic smooth muscle cells: comparison with vasoactive intestinal polypeptide. Biochem Cell Biol 71: 156-161.
15. Segment. Available: http://segment.heiberg.se. Images were analyzed using the freely available software Segment. Accessed 2013 Apr 11.
16. Morita H, Seidman J, Seidman CE, (2005) Genetic causes of human heart failure. J Clin Invest 115: 518-526.
17. NA (2013) Genetics Home Reference: Pulmonary arterial hypertension. U.S. National Library of Medicine. Available: http://ghr.nlm.nih.gov/condition/pulmonary-arterial-hypertension.
18. Haberl I, Frei K, Ramsebner R, Doberer D, Petkov V, et al. (2007) Vasoactive intestinal peptide gene alterations in patients with idiopathic pulmonary arterial hypertension. Eur J Hum Genet 15: 18-22.
19. Bronicki RA, Baden HP, (2010) Pathophysiology of right ventricular failure in pulmonary hypertension. Pediatr Crit Care Med 11: S15-22.
20. Seidman JG, Seidman C, (2001) The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 104: 557-567.
21. Watkins H, McKenna WJ, Thierfelder L, Suk HJ, Anan R, et al. (1995) Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med 332: 1058-1064.
22. Moolman JC, Corfield VA, Posen B, Ngumbela K, Seidman C, et al. (1997) Sudden death due to troponin T mutations. J Am Coll Cardiol 29: 549-555.
23. Anan R, Greve G, Thierfelder L, Watkins H, McKenna WJ, et al. (1994) Prognostic implications of novel beta cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy. J Clin Invest 93: 280-285.
24. Fujino N, Shimizu M, Ino H, Yamaguchi M, Yasuda T, et al. (2002) A novel mutation Lys273Glu in the cardiac troponin T gene shows high degree of penetrance and transition from hypertrophic to dilated cardiomyopathy. Am J Cardiol 89: 29-33.
25. Kokado H, Shimizu M, Yoshio H, Ino H, Okeie K, et al. (2000) Clinical features of hypertrophic cardiomyopathy caused by a Lys183 deletion mutation in the cardiac troponin I gene. Circulation 102: 663-669.
26. Regitz-Zagrosek V, Erdmann J, Wellnhofer E, Raible J, Fleck E, (2000) Novel mutation in the alpha-tropomyosin gene and transition from hypertrophic to hypocontractile dilated cardiomyopathy. Circulation 102: E112-116.
27. Milner DJ, Weitzer G, Tran D, Bradley A, Capetanaki Y, (1996) Disruption of muscle architecture and myocardial degeneration in mice lacking desmin. J Cell Biol 134: 1255-1270.
28. Arad M, Seidman JG, Seidman CE, (2002) Phenotypic diversity in hypertrophic cardiomyopathy. Hum Mol Genet 11: 2499-2506.
29. Kemp BE, Stapleton D, Campbell DJ, Chen ZP, Murthy S, et al. (2003) AMP-activated protein kinase, super metabolic regulator. Biochem Soc Trans 31: 162-168.
30. Wehrens XH, Lehnart SE, Reiken SR, Deng SX, Vest JA, et al. (2004) Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin2. Science 304: 292-296.
31. Frey N, Barrientos T, Shelton JM, Frank D, Rutten H, et al. (2004) Mice lacking calsarcin-1 are sensitized to calcineurin signaling and show accelerated cardiomyopathy in response to pathological biomechanical stress. Nat Med 10: 1336-1343.
32. Fatkin D, McConnell BK, Mudd JO, Semsarian C, Moskowitz IG, et al. (2000) An abnormal Ca(2+) response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy. J Clin Invest 106: 1351-1359.